Cytokinetics
CYTK
137 hedge funds and large institutions have $251M invested in Cytokinetics in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 52 increasing their positions, 35 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
49% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 35
12% more funds holding
Funds holding: 122 → 137 (+15)
1.96% more ownership
Funds ownership: 70.71% → 72.66% (+2%)
34% less capital invested
Capital invested by funds: $380M → $251M (-$129M)
43% less call options, than puts
Call options by funds: $314K | Put options by funds: $555K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.29M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.62M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$1.3M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.37M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.45M |
| 4 |
Millennium Management
New York
|
-$1.39M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.29M |
CYTK Hedge Fund Activity: Q4 2018 in Review
137 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2018, worth a combined $251M — down 34% from $380M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CYTK positions and 8 closed out — a net gain of 16 holders — while 52 added to existing stakes and 35 trimmed.
The largest buyer was Great Point Partners, adding an estimated $7.29M. The largest seller was BVF Inc, cutting an estimated $7.6M.
- 137 institutional investors held Cytokinetics (CYTK) as of Q4 2018, up from 122 in Q3 2018.
- Funds reported $251M of Cytokinetics stock for Q4 2018, down 34% quarter-over-quarter.
- 24 funds opened new Cytokinetics positions in Q4 2018 and 8 closed out, a net change of +16 holders.
- The largest Cytokinetics buyer in Q4 2018 was Great Point Partners, an estimated $7.29M added.
- The largest Cytokinetics seller in Q4 2018 was BVF Inc, an estimated $7.6M sold.
Based on aggregated 13F filings for Q4 2018.